Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Karas

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
American Journal of Public Health|February 22, 2019
Pharmaceutical Industry Support of US Patient Advocacy Organizations: An International ContextSo-Yeon Kang, Ge Bai, Laura Karas, et al.
Journal of the American Academy of Dermatology|May 20, 2019
The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancersLaura Karas, Christine Y Lu, Pankaj B Agrawal, et al.
The American Journal of Managed Care|April 19, 2018
Limited distribution networks stifle competition in the generic and biosimilar drug industriesLaura Karas, Kenneth M Shermock, Celia Proctor, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
American Journal of Public Health|February 22, 2019
Pharmaceutical Industry Support of US Patient Advocacy Organizations: An International ContextSo-Yeon Kang, Ge Bai, Laura Karas, et al.
Journal of the American Academy of Dermatology|May 20, 2019
The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancersLaura Karas, Christine Y Lu, Pankaj B Agrawal, et al.
The American Journal of Managed Care|April 19, 2018
Limited distribution networks stifle competition in the generic and biosimilar drug industriesLaura Karas, Kenneth M Shermock, Celia Proctor, et al.
Pageof 1